447 related articles for article (PubMed ID: 16889904)
1. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
2. Phyllodes tumor of the breast: stromal overgrowth and histological classification are useful prognosis-predictive factors for local recurrence in patients with a positive surgical margin.
Taira N; Takabatake D; Aogi K; Ohsumi S; Takashima S; Nishimura R; Teramoto N
Jpn J Clin Oncol; 2007 Oct; 37(10):730-6. PubMed ID: 17932112
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast.
Kuenen-Boumeester V; Henzen-Logmans SC; Timmermans MM; van Staveren IL; van Geel A; Peeterse HJ; Bonnema J; Berns EM
J Pathol; 1999 Oct; 189(2):169-75. PubMed ID: 10547570
[TBL] [Abstract][Full Text] [Related]
4. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
Kuijper A; de Vos RA; Lagendijk JH; van der Wall E; van Diest PJ
Am J Clin Pathol; 2005 May; 123(5):690-8. PubMed ID: 15981808
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
6. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
7. Phyllodes tumor of the breast.
Belkacémi Y; Bousquet G; Marsiglia H; Ray-Coquard I; Magné N; Malard Y; Lacroix M; Gutierrez C; Senkus E; Christie D; Drumea K; Lagneau E; Kadish SP; Scandolaro L; Azria D; Ozsahin M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):492-500. PubMed ID: 17931796
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
9. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer.
Yamashita H; Murakami N; Asari T; Okuma K; Ohtomo K; Nakagawa K
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1165-72. PubMed ID: 19101092
[TBL] [Abstract][Full Text] [Related]
10. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
11. Management of phyllodes breast tumors.
Guillot E; Couturaud B; Reyal F; Curnier A; Ravinet J; Laé M; Bollet M; Pierga JY; Salmon R; Fitoussi A;
Breast J; 2011; 17(2):129-37. PubMed ID: 21251125
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
13. Phyllodes tumor of the breast: an update.
Tse GM; Niu Y; Shi HJ
Breast Cancer; 2010; 17(1):29-34. PubMed ID: 19434472
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of the treatment and prognosis of recurrent breast phyllodes tumor].
Fang Y; Gao JD; Tian YT; Xie YQ; Zhen S
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):72-4. PubMed ID: 19538877
[TBL] [Abstract][Full Text] [Related]
15. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
16. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
17. P53 and MIB-1 expression in gastrointestinal stromal tumor (GIST) of the stomach.
Hata Y; Ishigami S; Natsugoe S; Nakajo A; Okumura H; Miyazono F; Matsumoto M; Hokita S; Aikou T
Hepatogastroenterology; 2006; 53(70):613-5. PubMed ID: 16995473
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
[TBL] [Abstract][Full Text] [Related]
19. Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.
Fajdić J; Gotovac N; Hrgović Z; Kristek J; Horvat V; Kaufmann M
Onkologie; 2007 Mar; 30(3):113-8. PubMed ID: 17341897
[TBL] [Abstract][Full Text] [Related]
20. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors.
Tse GM; Lui PC; Scolyer RA; Putti TC; Kung FY; Law BK; Lau TS; Lee CS
Mod Pathol; 2003 Oct; 16(10):1007-13. PubMed ID: 14559983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
